These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 25582328)

  • 21. Deciphering the link between PI3K and PAK: An opportunity to target key pathways in pancreatic cancer?
    Thillai K; Lam H; Sarker D; Wells CM
    Oncotarget; 2017 Feb; 8(8):14173-14191. PubMed ID: 27845911
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The discovery and the structural basis of an imidazo[4,5-b]pyridine-based p21-activated kinase 4 inhibitor.
    Park JK; Kim S; Han YJ; Kim SH; Kang NS; Lee H; Park S
    Bioorg Med Chem Lett; 2016 Jun; 26(11):2580-3. PubMed ID: 27117431
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Computational insight into the mechanisms of action and selectivity of Afraxis PAK inhibitors.
    Han D; Wang H; Cui W; Zhang B; Chen BZ
    Future Med Chem; 2020 Mar; 12(5):367-385. PubMed ID: 32064922
    [No Abstract]   [Full Text] [Related]  

  • 24. PB-10, a thiazolo[4,5-d] pyrimidine derivative, targets p21-activated kinase 4 in human colorectal cancer cells.
    Li R; Wang H; Wang J; Cheng M
    Bioorg Med Chem Lett; 2020 Jan; 30(2):126807. PubMed ID: 31740249
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 2-amino-N-{4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-phenyl} acetamide (OSU-03012), a celecoxib derivative, directly targets p21-activated kinase.
    Porchia LM; Guerra M; Wang YC; Zhang Y; Espinosa AV; Shinohara M; Kulp SK; Kirschner LS; Saji M; Chen CS; Ringel MD
    Mol Pharmacol; 2007 Nov; 72(5):1124-31. PubMed ID: 17673571
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structure-Based Design of 6-Chloro-4-aminoquinazoline-2-carboxamide Derivatives as Potent and Selective p21-Activated Kinase 4 (PAK4) Inhibitors.
    Hao C; Zhao F; Song H; Guo J; Li X; Jiang X; Huan R; Song S; Zhang Q; Wang R; Wang K; Pang Y; Liu T; Lu T; Huang W; Wang J; Lin B; He Z; Li H; Li F; Zhao D; Cheng M
    J Med Chem; 2018 Jan; 61(1):265-285. PubMed ID: 29190083
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery and the structural basis of a novel p21-activated kinase 4 inhibitor.
    Ryu BJ; Kim S; Min B; Kim KY; Lee JS; Park WJ; Lee H; Kim SH; Park S
    Cancer Lett; 2014 Jul; 349(1):45-50. PubMed ID: 24704155
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Computational insight into p21-activated kinase 4 inhibition: a combined ligand- and structure-based approach.
    Li RJ; Wang J; Xu Z; Huang WX; Li J; Jin SF; Zhao DM; Cheng MS
    ChemMedChem; 2014 May; 9(5):1012-22. PubMed ID: 24643945
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular pathways: targeting RAC-p21-activated serine-threonine kinase signaling in RAS-driven cancers.
    Baker NM; Yee Chow H; Chernoff J; Der CJ
    Clin Cancer Res; 2014 Sep; 20(18):4740-6. PubMed ID: 25225063
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of p21-activated kinases in cardiovascular development and function.
    Kelly ML; Astsaturov A; Chernoff J
    Cell Mol Life Sci; 2013 Nov; 70(22):4223-8. PubMed ID: 23640572
    [TBL] [Abstract][Full Text] [Related]  

  • 31. P21-activated kinase 4--not just one of the PAK.
    Dart AE; Wells CM
    Eur J Cell Biol; 2013; 92(4-5):129-38. PubMed ID: 23642861
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structure-Guided Design of Group I Selective p21-Activated Kinase Inhibitors.
    Crawford JJ; Lee W; Aliagas I; Mathieu S; Hoeflich KP; Zhou W; Wang W; Rouge L; Murray L; La H; Liu N; Fan PW; Cheong J; Heise CE; Ramaswamy S; Mintzer R; Liu Y; Chao Q; Rudolph J
    J Med Chem; 2015 Jun; 58(12):5121-36. PubMed ID: 26030457
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PAK signalling during the development and progression of cancer.
    Radu M; Semenova G; Kosoff R; Chernoff J
    Nat Rev Cancer; 2014 Jan; 14(1):13-25. PubMed ID: 24505617
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oncogenic PAK4 regulates Smad2/3 axis involving gastric tumorigenesis.
    Wang C; Li Y; Zhang H; Liu F; Cheng Z; Wang D; Wang G; Xu H; Zhao Y; Cao L; Li F
    Oncogene; 2014 Jun; 33(26):3473-84. PubMed ID: 23934187
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting the Ras-ERK pathway in pancreatic adenocarcinoma.
    Neuzillet C; Hammel P; Tijeras-Raballand A; Couvelard A; Raymond E
    Cancer Metastasis Rev; 2013 Jun; 32(1-2):147-62. PubMed ID: 23085856
    [TBL] [Abstract][Full Text] [Related]  

  • 36. P21-activated kinase 4 regulates the cyclin-dependent kinase inhibitor p57(kip2) in human breast cancer.
    Li Y; Wang D; Zhang H; Wang C; Dai W; Cheng Z; Wang G; Li F
    Anat Rec (Hoboken); 2013 Oct; 296(10):1561-7. PubMed ID: 23873832
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug discovery targeting p21-activated kinase 4 (PAK4): a patent review.
    Wang H; Song P; Gao Y; Shen L; Xu H; Wang J; Cheng M
    Expert Opin Ther Pat; 2021 Nov; 31(11):977-987. PubMed ID: 34369844
    [No Abstract]   [Full Text] [Related]  

  • 38. An anti-Ras cancer potential of PP1, an inhibitor specific for Src family kinases: in vitro and in vivo studies.
    He H; Hirokawa Y; Levitzki A; Maruta H
    Cancer J; 2000; 6(4):243-8. PubMed ID: 11038144
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MEK in cancer and cancer therapy.
    Neuzillet C; Tijeras-Raballand A; de Mestier L; Cros J; Faivre S; Raymond E
    Pharmacol Ther; 2014 Feb; 141(2):160-71. PubMed ID: 24121058
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lupeol, a fruit and vegetable based triterpene, induces apoptotic death of human pancreatic adenocarcinoma cells via inhibition of Ras signaling pathway.
    Saleem M; Kaur S; Kweon MH; Adhami VM; Afaq F; Mukhtar H
    Carcinogenesis; 2005 Nov; 26(11):1956-64. PubMed ID: 15958516
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.